Tag Archive: regulations

Laws, Regulations, Guidances, Guidelines and Best Practices

Bart Cobert attempts to clear up the confusion around Drug Safety and PV requirements in different regions of the world, with a focus on US and EU requirements.

Read More

Pharma’s Practical Next Steps for Social Media

What’s Next: Practical Steps for Pharma's Increased Social Media Participation

Read More

Bart’s Corner: Proposed MedWatch Changes

On December 11, 2014 FDA published in the Federal Register a notice about proposed changes in the MedWatch forms (3500A and B) for post-marketing SAE/AE reporting. The changes are largely cosmetic, though there is some increased collection of ethnic subgroup information. The proposed changes are detailed below. First, however, FDA[…]

Read More
Bart's Corner: REMS Update

Bart’s Corner: REMS Update

In September 2014 FDA issued a paper on Standardizing & Evaluating Risk Evaluation and Mitigation Strategy (REMS). A REMS is put in place for those products to ensure that benefits outweigh the risks. REMS may require additional measures above and beyond the usual post-marketing safety surveillance by the sponsor. This[…]

Read More
PV / Drug Safety Crises

Bart’s Corner: PV Crises

This is a follow up to the previous posting on PV Stress Tests. During every PV person’s career, a “PV crisis” will arise. PV “crises” can occur in clinical trials or during marketing and may be of varying degree and type; so let’s define them first. Although the following are[…]

Read More
5 Keys to Choosing the Right Healthcare IT Partner

5 Keys to Choosing the Right Healthcare IT Partner

As I mentioned in my last post, choosing an IT solutions provider is a critical decision for all healthcare leaders in their quest to stay competitive and offer cutting-edge technology. Here are 5 factors to consider when choosing the right healthcare IT partner: Cloud-Based Aptitude The future of the healthcare[…]

Read More

Bart’s Corner: EU Proposals on Updates for Good PV Practices

On September 15, 2014, the EMA published proposals on changes to the Good Pharmacovigilance (PV) Practices covering revisions of Module VI on the management and reporting of adverse reactions In particular post-authorisation safety studies and on Module III on new Union procedures for pharmacovigilance inspections. There is a request for[…]

Read More

Are You Missing the Interaction in Your Social Media Strategy?

The following post was adapted from You’ve Been Engaging, But Are You Interacting? on JohnMacDaniel.net. Much has been written about brands and the need to create content on their branded social media properties that encourages their community to engage. The power of compelling content and the consumer that can’t help[…]

Read More

Bart’s Corner: Escalating Signals and Safety Issues

In modern day pharmacovigilance (PV) and Drug Safety (DS), whether it is done in companies or health authorities, it is absolutely necessary to have in place a mechanism both to identify safety issues and then to act on them. There has been much discussion about the identification of safety issues[…]

Read More

Bart’s Corner: Update on EMA Risk Management Plans (RMPs)

In April of this year the EMA announced the first public summary of an RMP, in this case for the drug Neuraceq [florbetaben (18F)] The EMA also published an update of their webpage on RMPs, which noted that the revision to the Good PV Practice RMP module – Module V[…]

Read More

The Experience Matters.

As an industry leader in business process outsourcing, C3i Solutions delivers global, multi-channel engagement solutions. The Experience Matters. Let us show you why.

Contact Us